Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

768
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
768
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

3.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

720
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
720
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

273
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
273
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

821
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
821
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

225
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
225

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Circulating nitric oxide pathway metabolites in heart failure with preserved ejection fraction: a sex-stratified cross-sectional analysis.

Biology of sex differences·2026
Same author

Stroke and its consequences: protocol and pilot data of the observational Berlin Long-term Observation of Vascular Events (BeLOVE) stroke stratum.

BMJ neurology open·2026
Same author

Circulating nitric oxide pathway metabolites in heart failure with preserved ejection fraction: a sex-stratified cross-sectional analysis.

Biology of sex differences·2026
Same author

Wearables for Telemonitoring in ATTR-Amyloidosis: Current Perspectives.

Sensors (Basel, Switzerland)·2026
Same author

Identification of Autologous Tissue Sources and Optimization of a Treatment Method for Intraoperative Manufacturing of Heart Valve Constructs.

Artificial organs·2026
Same author

Health status and effects of spironolactone in people at high risk of heart failure: The Heart OMics in AGEing (HOMAGE) randomized trial.

Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology·2026
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
See all related articles

Related Experiment Video

Updated: Jan 20, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.0K

[Heart failure with preserved left ventricular ejection fraction].

Johannes Petutschnigg1,2, Frank Edelmann3,4,5

  • 1Medizinische Klinik mit Schwerpunkt Kardiologie, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin, Deutschland.

Der Internist
|August 22, 2019
PubMed
Summary
This summary is machine-generated.

Heart failure with preserved ejection fraction (HFpEF) affects many patients, but effective treatments are limited. This review examines current therapies, their risks, and promising future treatments for HFpEF management.

Keywords:
DiagnosticDysfunction, diastolicHeart failure, diastolicPrognosisTherapy

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.3K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.0K

Related Experiment Videos

Last Updated: Jan 20, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.0K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.3K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.0K

Area of Science:

  • Cardiology
  • Internal Medicine
  • Clinical Research

Background:

  • Heart failure is a leading inpatient diagnosis in Germany.
  • Heart failure with preserved ejection fraction (HFpEF) accounts for half of all heart failure cases.
  • HFpEF diagnosis requires clinical signs, echocardiography, and cardiac biomarkers.

Purpose of the Study:

  • To review current and potential treatments for HFpEF.
  • To discuss the efficacy and risks of existing HFpEF therapies.
  • To provide insights into novel treatments in clinical trials.

Main Methods:

  • Literature review of current treatment guidelines and clinical trial data for HFpEF.
  • Analysis of etiological and pathophysiological classifications of heart failure.
  • Discussion of verified and experimental therapeutic strategies.

Main Results:

  • Effective treatment options for HFpEF remain limited.
  • Some verified treatments may offer benefits, while others could be harmful.
  • Several novel substances are in advanced clinical trial stages for HFpEF.

Conclusions:

  • HFpEF is a complex and heterogeneous condition requiring careful treatment selection.
  • Further research and clinical trials are crucial for developing effective HFpEF therapies.
  • Future treatments hold promise for improving outcomes in HFpEF patients.